Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Private Advisor Group LLC

Private Advisor Group LLC cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 10.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,767 shares of the medical research company’s stock after selling 211 shares during the quarter. Private Advisor Group LLC’s holdings in Charles River Laboratories International were worth $348,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Tortoise Investment Management LLC lifted its holdings in Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares during the period. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $32,000. Headlands Technologies LLC acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth approximately $41,000. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Charles River Laboratories International by 219.3% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after buying an additional 193 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $79,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CRL. Robert W. Baird reduced their target price on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Redburn Atlantic began coverage on Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 target price for the company. UBS Group reduced their price objective on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. StockNews.com raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, October 16th. Finally, Barclays reduced their price objective on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $209.00.

Charles River Laboratories International Stock Up 3.5 %

Shares of NYSE:CRL opened at $188.90 on Wednesday. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65. The business has a fifty day moving average of $193.28 and a two-hundred day moving average of $208.83. The stock has a market cap of $9.75 billion, a P/E ratio of 22.24, a PEG ratio of 6.20 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52-week low of $166.87 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.41. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. On average, research analysts expect that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International declared that its board has authorized a share repurchase program on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its stock is undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).